Abstract
Therapeutic management of patients with immune thrombocytopenia (ITP) remains challenging; however, thrombopoietin receptor agonists (TPO-RAs) have revolutionised the treatment landscape of ITP. It is increasingly hypothesised that TPO-RAs may have an immune modulatory role and Pizzi and colleagues provide evidence in support of this by demonstrating that TPO-RA treatment restores the decreased regulatory T cell (Treg) numbers in the splenic microenvironment of patients with ITP. Commentary on: Pizzi M, Vianello F, Binotto G, Vianelli N, Carli G, Auteri G, et al. Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in Immune Thrombocytopenia. Br J Haematol. 2022;198:916-922.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
